Shmuel Cabilly, Ph.D.
Shmuel Cabilly, Ph.D., is a leading scientist and inventor in the field of immunology. His patented inventions related to recombinant antibody production have led to the development of widely used drugs, such as Herceptin, Rituxan, Avestin and others.
Dr. Cabilly was the co-founder and chief scientist of Ethrog Biotechnology, where he invented dry buffer technologies that enable the production of a disposable apparatus for gel electrophoresis containing no liquid and a technology that enables the condensation of molecule separation zones to a small gel area.
Dr. Cabilly holds a Ph.D in Immunology from the Hebrew University in Jerusalem.